This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Entasis' (ETTX) Phase III Study on Infection Drug Meets Goal
by Zacks Equity Research
Entasis' (ETTX) phase III ATTACK study achieves primary endpoint. The study evaluates its investigational combo drug SUL-DUR in infections caused by Acinetobacter baumannii.
United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA (Revised)
by Zacks Equity Research
United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.
United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA
by Zacks Equity Research
United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.
Wall Street Analysts See a 55% Upside in Xencor (XNCR): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 55.4% upside potential for Xencor (XNCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Xencor (XNCR) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Xencor (XNCR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Top Ranked Momentum Stocks to Buy for October 7th
by Zacks Equity Research
XNCR, ARCB, RRC, and NTR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 7, 2021
Xencor (XNCR) Inks Deal With J&J for B-Cell Malignancy Treatment
by Zacks Equity Research
Xencor (XNCR) partners will J&J (JNJ) to develop and commercialize bispecific antibody candidates against B-cell malignancy. Resultantly, the stock gains.
Xencor (XNCR) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of 242.62% and 296.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Down 10.9% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround
by Zacks Equity Research
Xencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Savara (SVRA) Initiates Dosing in Pivotal Lung Disorder Study
by Zacks Equity Research
Savara (SVRA) is developing its lead pipeline candidate, molgramostim, as a potential treatment for autoimmune pulmonary alveolar proteinosis.
Jazz Pharma (JAZZ) Gets FDA Approval for Leukemia Drug Rylaze
by Zacks Equity Research
Jazz Pharma (JAZZ) gets FDA approval for Rylaze to treat acute lymphoblastic leukemia or lymphoblastic lymphoma with hypersensitivity to asparaginase.
Xencor (XNCR) Loses 12.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Xencor (XNCR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics
4 Small Drug Stocks Set to Escape the COVID-Led Industry Weakness
by Kinjel Shah
Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry in the second quarter of 2021. However, with demand trends expected to improve, XNCR, ORGO, CPIX, and ACER may prove to be good additions to one's portfolio.
Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor
by Zacks Equity Research
Omeros (OMER) announces initial results from a phase I study of OMS906.
Amryt (AMYT) NDA for Skin Disorder Drug Gets Priority Review
by Zacks Equity Research
Amryt (AMYT) is seeking approval for Oleogel-S10 as a potential treatment for patients with rare and distressing genetic skin disorder, epidermolysis bullosa.
United Therapeutics (UTHR) Begins TETON Study on Tyvaso in IPF
by Zacks Equity Research
United Therapeutics (UTHR) enrolls the first patient in the phase III TETON study evaluating Tyvaso for treating adult patients with idiopathic pulmonary fibrosis.
Verrica's (VRCA) Skin Disease Candidate Approval Gets Delayed
by Zacks Equity Research
Verrica's (VRCA) NDA for lead candidate, VP-102, a drug-device combination treatment for skin disease, molluscum, is under review. FDA delays decision on potential approval for the candidate by three months.
Minerva (NERV) Soars on Promising Schizophrenia Study Data
by Zacks Equity Research
Minerva (NERV) is developing its lead pipeline candidate, roluperidone, in patients with negative symptoms of schizophrenia. Positive data from an extension of previously completed late-stage study boosts investors' sentiment.
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of 94.81% and 160.31%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of 55.56% and 97.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) Inks Deal for Novel Antibody Therapies in Cancer
by Zacks Equity Research
Xencor (XNCR) signs a strategic research collaboration deal with MD Anderson Cancer Center to develop and commercialize T Cell-engaging bispecific antibodies for treating cancer.
Incyte (INCY), Xencor and MorphoSys Ink Collaboration Deal
by Zacks Equity Research
Incyte (INCY), Xencor and MorphoSys ink deal to evaluate the combination of tafasitamab, plamotamab and lenalidomide in lymphoma indications.
Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of 0.00% and -2.45%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?